IBRX ImmunityBio Inc

Price (delayed)

$10.36

Market cap

$4.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$4.3B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's equity has shrunk by 193% YoY but it has increased by 15% QoQ
ImmunityBio's quick ratio has plunged by 78% YoY but it has increased by 33% from the previous quarter
ImmunityBio's net income has shrunk by 85% YoY and by 20% QoQ
ImmunityBio's EPS has shrunk by 68% YoY and by 11% QoQ

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
391.16M
Market cap
$4.05B
Enterprise value
$4.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7,031.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7,584.16
Earnings
Revenue
$567,000
EBIT
-$215.03M
EBITDA
-$199.03M
Free cash flow
-$188.63M
Per share
EPS
-$0.94
Free cash flow per share
-$0.49
Book value per share
-$0.41
Revenue per share
$0
TBVPS
$0.64
Balance sheet
Total assets
$246.3M
Total liabilities
$404.89M
Debt
$331.8M
Equity
-$157.94M
Working capital
$39.3M
Liquidity
Debt to equity
-2.1
Current ratio
1.53
Quick ratio
1.42
Net debt/EBITDA
-1.25
Margins
EBITDA margin
-35,102.1%
Gross margin
100%
Net margin
-39,119.9%
Operating margin
-39,679.5%
Efficiency
Return on assets
-103.5%
Return on equity
N/A
Return on invested capital
-63.2%
Return on capital employed
-125.1%
Return on sales
-37,923.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
-2.91%
1 week
4.54%
1 month
-8.48%
1 year
N/A
YTD
N/A
QTD
-27.45%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$567,000
Gross profit
$567,000
Operating income
-$224.98M
Net income
-$221.81M
Gross margin
100%
Net margin
-39,119.9%
ImmunityBio's operating margin has plunged by 106% YoY and by 39% from the previous quarter
The net margin has dropped by 103% year-on-year and by 40% since the previous quarter
IBRX's operating income has dropped by 88% year-on-year and by 18% since the previous quarter
ImmunityBio's net income has shrunk by 85% YoY and by 20% QoQ

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
7,031.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7,584.16
ImmunityBio's EPS has shrunk by 68% YoY and by 11% QoQ
ImmunityBio's equity has shrunk by 193% YoY but it has increased by 15% QoQ
The P/S is 22% less than the last 4 quarters average of 9229.6 and 3.2% less than the 5-year quarterly average of 7478.0
ImmunityBio's revenue has decreased by 15% QoQ and by 9% YoY

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has shrunk by 104% YoY and by 40% QoQ
The company's return on invested capital rose by 37% YoY and by 9% QoQ
IBRX's return on assets is down by 35% year-on-year and by 13% since the previous quarter

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 39% less than the total liabilities
ImmunityBio's quick ratio has plunged by 78% YoY but it has increased by 33% from the previous quarter
The current ratio has plunged by 77% YoY but it has increased by 22% from the previous quarter
ImmunityBio's equity has shrunk by 193% YoY but it has increased by 15% QoQ
The company's debt to equity fell by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.